s6y BRAINSTORM CELL THERAPEUTICS INC. CORRESP

BRAINSTORM CELL THERAPEUTICS INC. CORRESP, filed Feb 27, 2012: filename1.htm

 

 

February 27, 2012

 

Jeffrey P. Riedler
Assistant Director
Securities and Exchange Commission (Mail Stop 4561)
100 F Street, N.E.
Washington, D.C. 20549

 

Re: Brainstorm Cell Therapeutics Inc.
  Registration Statement on Form S-1
  Filed February 3, 2012
  File No. 333-179331

 

Dear Mr. Riedler:

 

We are in receipt of the letter dated February 14, 2012 from the Staff of the U.S. Securities and Exchange Commission containing comments on our above-captioned filing (the “Comment Letter”).

 

We are currently finalizing our audit of our financial statements for the year ended December 31, 2011. We anticipate that we can file an amendment to our S-1 Registration Statement which will include these audited financial statements the week of March 12th. We hereby request an extension for submitting a response to the Comment Letter. With such amendment, we will file a response letter to the Comment Letter and amend the S-1 accordingly.

 

If you have any questions with regards to this request please contact the undersigned at +972 3 923 6384 or Thomas Rosedale of BRL Law Group LLC at (617) 399-6935.

 

 

 

 

Very truly yours,

 

/s/ Liat Sossover

 

Liat Sossover 

 

 

Copy to: Thomas B. Rosedale, Esq.

 


 

BrainStorm Cell Therapeutics Inc.
605 Third Avenue, 34th Floor
New York NY 10158
Tel:  (646) 666 3188

BrainStorm Cell Therapeutics Ltd.
12 Bazel St., POB 10019 Kiryat Aryeh,
Petach Tikva, Israel 49001
Tel: (972) 3.923.6384

Fax: (212) 286-1884
E-mail: info@brainstorm-cell.com